Accuray vs NovoCure
ARAY and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARAY and NVCR compare
NovoCure is the larger company, worth 4.1 times as much as Accuray ($1.4B against $334M).
NovoCure grew revenue faster over the last twelve months (12.9% versus −12.5% for Accuray).
Accuray keeps more of each dollar of sales as profit, with a net margin of −4.4% compared with −16.8% at NovoCure.
NovoCure scores higher on the StockData Score (9 against 3 for Accuray), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARAY | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $334M | $1.4B |
| Share price | $2.80 | $11.83 |
| Change, 1 year | −94.1% | 4.1% |
| Change, 5 years | −98.7% | −88.6% |
| Beta (5Y) | 0.73 | 1.57 |
| Employees | 809 | 1,605 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 1.9× |
| P/B | 6.3× | 3.9× (better) |
| FCF yield | −8.1% | −1.8% (better) |
| Fair value | – | $16.23 |
| Margin of safety | – | 27.1% |
| Growth | ||
| Revenue growth (TTM) | −12.5% | 12.9% (better) |
| Revenue growth, 5Y average | 0.28% | 5.8% (better) |
| Profitability | ||
| Gross margin | 28.0% | 77.0% (better) |
| Operating margin | −13.1% (better) | −17.2% |
| Net margin | −4.4% (better) | −16.8% |
| FCF margin | −6.9% | −3.4% (better) |
| Return on equity | −30.2% (better) | −35.2% |
| Return on invested capital | −30.9% (better) | −70.8% |
| Financial health | ||
| Debt / equity | 1.91 | 0.07 (better) |
| Interest coverage | −1.4× | – |
| Current ratio | 1.56 | 2.49 (better) |
| Altman Z-score | −0.54 | 0.35 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.26% |
| Shareholder yield | 0.00% (better) | −0.26% |
| Ownership | ||
| Held by institutions | 59.9% | 88.5% |
| Held by insiders | 28.7% | 3.0% |
| Insider net buying, 12 months | $134K (better) | −$3.4M |
| Short interest, % of float | 6.6% | 11.4% |
Go deeper
- ARAY stock overview
- ARAY income statement
- ARAY valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.